A comparative study on the safety and immunogenicity of purified duck embryo cell vaccine (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab)

Rabies is a fatal but preventable disease Cell culture vaccines (CCV) and purified cluck embryo vaccines (PDEV) are currently recommended by WHO for post-exposure prophylaxis In India, a PDEV (Vaxirab) is being manufactured and is in use since 2003 In the present study, we have evaluated the safety. immunogenicity and tolerance of this vaccine with two other WHO approved CCVS, VIZ, Purified chick embryo cell vaccine (PCEC. Rabipur) and purified vero cell rabies vaccine (PVRV. Veroroab) This Study was an open label, randomized phase IV comparative clinical trial A total of 152 people bitten by dogs and other animals were recruited from 4 different centres from India. They were randomly assigned to receive one of the vaccines by Essen intramuscular regimen (52 subjects received Vaxirab and 50 each Rabipur and Verorab) and rabies immunoglobulin was also administered in all category III exposures Their blood samples were collected on day 0 (prior to vaccination), 14, 28, 90 and 180 Side effects if any were monitored The rabies neutralizing antibody titers in their blood samples were estimated by the rapid fluorescent focus inhibition test (RFFIT) Subjects in all three groups had neutralizing antibody titers by day 14 (>0.5 IU/mL) and geometric mean titers (GMT) observed for different vaccines on all days tested did not vary significantly (p > 0 5). Side effects observed were minimal and did not vary significantly among the groups. The results of the present study indicate that PDEV (Vaxirab) is as safe, tolerable and immunogenic as both PCEC (Rabipur) and PVRV (Verorab) Thus this vaccine can be a good alternative to WHO approved CCVs for rabies post-exposure prophylaxis (C) 2009 Elsevier Ltd All rights reserved